KFF analysis finds TrumpRx prices mixed against peer countries

September 30, 2026 at 12:36 AM2 min

This digest was compiled by AI from multiple sources — links to the originals are below.

A KFF analysis of 32 brand-name drugs on TrumpRx found prices lower than peer-country averages for 17 drugs and higher for 15. The nonpartisan health policy group said there is no consistent pattern of lower prices. The U.S. Department of Health and Human Services said the program has delivered $700 million in savings.

Key Facts

KFF analyzed 32 brand-name drugs without generics listed on TrumpRx that had publicly available prices in peer countries.
For 17 of the 32 drugs, the TrumpRx price was lower than the average price in other countries.
For 15 of the 32 drugs, the TrumpRx price was higher than the average price in other countries.
13 drugs have higher prices on TrumpRx than in any other country included in the comparison.
The U.S. Department of Health and Human Services cited $700 million in prescription drug savings through TrumpRx.

KFF Price Comparison

KFF analyzed 32 brand-name drugs without generics listed on TrumpRx that had publicly available prices in comparable peer countries, including Australia, Canada, France, Germany, Japan, and the United Kingdom. For 17 of the 32 drugs, the TrumpRx price was lower than the average price in other countries. For the remaining 15 drugs, the TrumpRx price was higher than the average price in other countries. 13 drugs have higher prices on TrumpRx than in any other country included in the comparison. Juliette Cubanski, vice president and director of the program on Medicare policy at KFF, said there is no across-the-board pattern of higher or lower prices.

Administration Response

A representative from the U.S. Department of Health and Human Services said TrumpRx continues to deliver measurable savings for American patients nationwide. The representative cited $700 million in prescription drug savings for Americans through the program. The lower costs for brand-name drugs on the TrumpRx platform are available through Most Favored Nation price agreements with drug manufacturers. Brand-name drugs with Most Favored Nation pricing are listed on TrumpRx as Presidential deals.

Broader Price Trends

AARP published a report in May showing that prices for some brand-name drugs have increased in the U.S. while decreasing in other countries. In an analysis of 25 brand-name drugs, AARP found that U.S. list prices had increased by an average of 81% since the drugs entered the market. Prices across 19 other high-income countries decreased by an average of 13%. The AARP report acknowledged efforts to address the issue, including the administration's push for Most Favored Nation pricing.